C 101

Drug Profile

C 101

Alternative Names: C-101; Myodur

Latest Information Update: 27 Apr 2009

Price : $50

At a glance

  • Originator CepTor Corporation
  • Class
  • Mechanism of Action Calpain inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Muscular dystrophies

Highest Development Phases

  • Discontinued Muscular dystrophies

Most Recent Events

  • 11 Sep 2006 CepTor has filed an IND Complete Response with the FDA in the USA for Duchenne muscular dystrophy
  • 25 Apr 2006 Preclinical data from a media release have been added to the Musculoskeletal disorders pharmacodynamics section
  • 25 Jan 2006 C 101 has received Orphan Drug Status for Duchenne's and Becker muscular dystrophies in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top